Similar articles

• The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma.

  Bast RC Jr, Knapp RC. Bast RC Jr, et al. Important Adv Oncol. 1987:39-53. Important Adv Oncol. 1987. PMID: 3331386 Review. No abstract available.
• [REGAJ diagnosis of recurrence of ovarian cancer].

  Paterok EM, Jäger W, Feistel H, Lang N, Wolf F. Paterok EM, et al. Gynakol Rundsch. 1989;29 Suppl 2:360-3. Gynakol Rundsch. 1989. PMID: 2613050 German. No abstract available.
• [Clinical relevance of tumor markers for follow-up and therapy planning in ovarian cancer].

  Böhm W, Lücke R, Ertle B, Benz R, Deinert S. Böhm W, et al. Arch Gynecol Obstet. 1989;245(1-4):640-2. doi: 10.1007/BF02417474. Arch Gynecol Obstet. 1989. PMID: 2802749 German. No abstract available.
• Influence of human anti-murine antibodies on in vitro assays in ovarian cancer patients.

  Hertel A, Baum R. Hertel A, et al. Hybridoma. 1993 Oct;12(5):571-6. doi: 10.1089/hyb.1993.12.571. Hybridoma. 1993. PMID: 8300132 No abstract available.
• CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancer.

  Kenemans P. Kenemans P. Eur J Obstet Gynecol Reprod Biol. 1990 Sep;36(3):221-8. doi: 10.1016/0028-2243(90)90201-b. Eur J Obstet Gynecol Reprod Biol. 1990. PMID: 2199246 Review. No abstract available.